N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=272 A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
Atrial Fibrillation
Primary: Number of Participants With Primary Adverse Events (PAEs) — 0; 0; 0 Participants
Phase 4 N=55 Ablation of the Pulmonary Veins for Paroxysmal Afib
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Successful Pulmonary Vein Isolation — 53 participants
N/A N=149 A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator
Atrial Fibrillation
Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants
N/A N=177 A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator
Atrial Fibrillation
Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0; 0; 0; 0 Percentage of participants
N/A N=15 A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants
N/A N=25 Atrial Fibrillation Recurrence in Sleep Apnea
Sleep Apnea · Atrial Fibrillation
Primary: Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year — 3; 3 participants
Phase 1 N=48 A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF — 0; 2; 0; 0 Participants
N/A N=109 Effect of Treatment of Sleep Apnea in Patients With Paroxysmal Atrial Fibrillation
Sleep Disordered Breathing · Sleep Apnea · Paroxysmal Atrial Fibrillation
Primary: Change in AF Burden — 5.6; 5.0; 4.1; 4.3 percentage of time in AF — p=0.520
N/A N=320 Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Recurrent Atrial Fibrillation — 60; 31 Participants
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
N/A N=607 The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants
Phase 4 N=102 Electrophysiologically Guided PAcing Site Selection Study
Sinus Arrhythmia · Atrial Fibrillation
Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2…
Phase 3 N=353 HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description — 102; 103 Successful Participants
N/A N=28 Feasibility Study of the FARAPULSE Endocardial Multi Ablation System in the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Safety at 30 Days — 1 Participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=421 Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Atrial Fibrillation
Primary: Safety: Number of Participants With at Least One Primary Safety Event — 1; 1 Participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=355 TactiFlex Paroxysmal Atrial Fibrillation IDE Trial
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Device or Procedure-related Serious Adverse Events — 12; 2 Participants
N/A N=30 A RWS of the FARAPULSE in A Chinese Population With PAF
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Acute Procedural Success — 30 Participants
N/A N=669 A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure — 2.3; 2.4 Percentage of participants
Phase 2 N=186 REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants
Phase 3 N=210 Tailored Treatment of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
Phase 4 N=83 Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
Atrial Fibrillation
Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
N/A N=402 Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)
Paroxysmal Atrial Fibrillation (PAF)
Primary: Effectiveness: Percentage of Participants Free of Chronic Treatment Failure (CTF) Through 36 Months — 66.9 Percentage of participants — p=<0.001
N/A N=71 A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Primary Safety Endpoint for This Study is the Composite Safety Endpoint (CSE) Defined as the Proportion of Patients With Early-onset and Late-onset Serious Adverse…
N/A N=60 Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent AF
Persistent Atrial Fibrillation
Primary: Percentage of Participants With Acute Success Post CartoFinder Guided Ablation (CFGA) Only (Before Pulmonary Vein Isolation [PVI] and Without Cardioversion). — 22.9…
Phase 3 N=258 A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Acute Procedural Success (APS) — 160 participants